Skip to main content
. 2017 Mar 6;75(1):97–107. doi: 10.1097/QAI.0000000000001342

FIGURE 2.

FIGURE 2.

Sustained virologic response (mITT) by HCV GT and use of ARV drug classes. CI, confidence interval; INI, integrase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; SVR12, sustained virologic response at posttreatment week 12; VF, virologic failure; wk, weeks. *Excludes 1 GT 2 (achieved SVR12), 1 GT 6 (SVR12), and 5 missing GT (4 SVR12) patients. †Excludes 14 patients without ARV usage data (all SVR12).